High‐resolution metabolomic profiling of Alzheimer’s disease in plasma

• Published in: Annals of clinical and translational neurology Vol. 7; no. 1; pp. 36 - 45
• Main Authors: Niedzwiecki, Megan M., Walker, Douglas I., Howell, Jennifer Christina, Watts, Kelly D., Jones, Dean P., Miller, Gary W., Hu, William T.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.01.2020; John Wiley and Sons Inc; Wiley
• Subjects: Accuracy; Age; Aged; Aged, 80 and over; Alkaloids - blood; Alzheimer Disease - blood; Alzheimer Disease - cerebrospinal fluid; Alzheimer's disease; Benzodioxoles - blood; Biomarkers; Brain research; Chromatography, Liquid; Cognitive ability; Cognitive Dysfunction - blood; Cognitive Dysfunction - cerebrospinal fluid; Dementia; Female; Fourier transforms; Glutamine - blood; Humans; Male; Mass Spectrometry; Metabolites; Metabolome; Metabolomics - methods; Middle Aged; Pathology; Piperidines - blood; Polyunsaturated Alkamides - blood; Studies; Systematic review
• ISSN: 2328-9503; 2328-9503
• DOI: 10.1002/acn3.50956

Background Alzheimer’s disease (AD) is a complex neurological disorder with contributions from genetic and environmental factors. High‐resolution metabolomics (HRM) has the potential to identify novel endogenous and environmental factors involved in AD. Previous metabolomics studies have identified circulating metabolites linked to AD, but lack of replication and inconsistent diagnostic algorithms have hindered the generalizability of these findings. Here we applied HRM to identify plasma metabolic and environmental factors associated with AD in two study samples, with cerebrospinal fluid (CSF) biomarkers of AD incorporated to achieve high diagnostic accuracy. Methods Liquid chromatography‐mass spectrometry (LC–MS)‐based HRM was used to identify plasma and CSF metabolites associated with AD diagnosis and CSF AD biomarkers in two studies of prevalent AD (Study 1: 43 AD cases, 45 mild cognitive impairment [MCI] cases, 41 controls; Study 2: 50 AD cases, 18 controls). AD‐associated metabolites were identified using a metabolome‐wide association study (MWAS) framework. Results An MWAS meta‐analysis identified three non‐medication AD‐associated metabolites in plasma, including elevated levels of glutamine and an unknown halogenated compound and lower levels of piperine, a dietary alkaloid. The non‐medication metabolites were correlated with CSF AD biomarkers, and glutamine and the unknown halogenated compound were also detected in CSF. Furthermore, in Study 1, the unknown compound and piperine were altered in MCI patients in the same direction as AD dementia. Conclusions In plasma, AD was reproducibly associated with elevated levels of glutamine and a halogen‐containing compound and reduced levels of piperine. These findings provide further evidence that exposures and behavior may modify AD risks.